Dan Hicklin
About Dan Hicklin
Dan Hicklin's Professional Background
Dan Hicklin serves as the President, Chief Executive Officer, and Board member of Werewolf Therapeutics, which he founded in October 2017. Prior to this, he has held notable positions in the biotechnology and pharmaceutical sectors, such as Executive Partner at MPM Capital from 2014 to December 2019. He also founded Potenza Therapeutics, Inc. and served as its President and CEO until its acquisition by Astellas Pharma Inc. in December 2018. Earlier in his career, he was the President and Chief Scientific Officer at CoStim Pharmaceuticals, Inc., which was acquired by Novartis in February 2014.
Dan Hicklin's Educational Background
Dan Hicklin holds a Ph.D. in Microbiology and Immunology from New York Medical College, where he trained under Dr. Soldano Ferrone. He also obtained a Bachelor of Science degree from the University of Iowa. His academic background laid a strong foundation for his significant contributions to the field of immuno-oncology.
Dan Hicklin's Industry Roles and Contributions
Dan Hicklin has an extensive history of leadership roles within the industry. At Merck Research Laboratories, he assumed several positions, including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. Furthermore, he served at Imclone Systems Incorporated as Vice President, Experimental Therapeutics. Currently, he is also part of the Industry Advisory Committee for The Mark Foundation for Cancer Research, contributing his expertise to advancing cancer research.
Dan Hicklin's Role at Werewolf Therapeutics
Dan Hicklin is the founder and current President, CEO, and Board member of Werewolf Therapeutics, established in October 2017. Under his leadership, the company focuses on developing innovative immune-oncology therapies designed to activate and harness the body's immune system to fight cancer.